| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, we evaluated the feasibility of PET study using fluorothymidine (FLT), which is a derivative of thymidine, and compared with conventional FDG PET in patients with cardiac sarcoidosis. The FLT accumulation of both cardiac and extra-cardiac lesions was significantly lower than those of FDG accumulation. However, the accuracy of FLT PET was comparable to FDG PET as for diagnosing cardiac sarcoidosis. Furthermore, The FLT accumulation of both cardiac and extra-cardiac lesions after therapy were lower than those of before therapy.
The present study indicates that FLT PET, even without the usually necessary preparation, could have the potential to diagnose cardiac sarcoidosis and identify the therapeutic response in patients with cardiac sarcoidosis.
|
